# GRI Bio Announces Closing of $8.0 Million Public Offering
Canonical URL: https://biopharmsignal.com/news/GRI/gri-bio-announces-closing-of-8-0-million-public-offering
Ticker: GRI
Company: GRI Bio
Source: GRI Bio
Published: 2025-12-12 16:05 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify"><strong>LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- </strong>GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative 

## Article Body
LA JOLLA, CA, Dec.  12, 2025  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced...
## Recent Company News
- 2026-06-18 13:31 EST — [GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis](https://biopharmsignal.com/news/GRI/gri-bio-secures-fda-orphan-drug-designation-for-gri-0621-tazarotene-in-idiopathi-36c7f058) — Source: GRI Bio
- 2026-05-14 08:35 EST — [GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline](https://biopharmsignal.com/news/GRI/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-immune-modulating-pipeline) — Source: GRI Bio
- 2026-04-08 08:30 EST — [GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions](https://biopharmsignal.com/news/GRI/gri-bio-receives-notice-of-allowance-for-uae-patent-application-covering-novel-type-2-diverse-nkt-cell-agonists-for-the-treatment-of-inflammatory-conditions) — Source: GRI Bio
- 2026-02-17 09:15 EST — [GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment](https://biopharmsignal.com/news/GRI/gri-bio-ceo-marc-hertz-featured-in-virtual-investor-what-this-means-segment) — Source: GRI Bio
- 2026-02-05 09:15 EST — [GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial](https://biopharmsignal.com/news/GRI/gri-bio-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial) — Source: GRI Bio
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)